• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Materials Science & Engineering >Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development
【24h】

Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development

机译：微针阵列作为透皮和皮内药物输送系统：材料科学，制造和商业开发

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Transdermal drug delivery offers a number of advantages for the patient, due not only its non-invasive and convenient nature, but also factors such as avoidance of first pass metabolism and prevention of gastrointestinal degradation. It has been demonstrated that microneedle arrays can increase the number of compounds amenable to transdermal delivery by penetrating the skin's protective barrier, the stratum corneum, and creating a pathway for drug permeation to the dermal tissue below. Microneedles have been extensively investigated in recent decades for drug and vaccine delivery as well as minimally invasive patient monitoring/diagnosis. This review focuses on a range of critically important aspects of microneedle technology, namely their material composition, manufacturing techniques, methods of evaluation and commercial translation to the clinic for patient benefit and economic return. Microneedle research and development is finally now at the stage where commercialisation is a realistic possibility. However, progress is still required in the areas of scaled-up manufacture and regulatory approval.
机译：透皮药物递送不仅为患者提供无创和方便的性质，而且由于诸如避免首过代谢和预防胃肠道降解等因素，为患者提供了许多优势。已经证明，微针阵列可以穿透皮肤的保护性屏障，角质层，并为药物渗透到下面的真皮组织创造途径，从而增加适合经皮递送的化合物的数量。近几十年来，微针已广泛用于药物和疫苗的输送以及对患者的微创监测/诊断。这篇综述着重介绍了微针技术的一系列至关重要的方面，即它们的材料组成，制造技术，评估方法以及将其商业化转译至临床以使患者受益并带来经济回报。现在，微针的研发终于处于商业化成为现实的阶段。但是，在规模化制造和法规批准方面仍需要进步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号